Physician profile
Samuel Muench
NPI 1164871562
$34,126.77
in general payments reported to CMS, 2019-2025
35 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $906 · 2023: $2,138 · 2024: $5,080 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $11K · Travel and Lodging: $1,074 · Education: $3.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,012.50 |
| Food and Beverage | $10,900.98 |
| Travel and Lodging | $1,074.18 |
| Education | $3.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $13,804.11 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $8,142.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Biotech, INC. | $2,808.57 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $1,257.72 | 2022-2024 | Zeposia |
| Abbvie INC. | $1,249.38 | 2021-2025 | |
| Pfizer INC. | $723.67 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $614.90 | 2023-2025 | Dupixent |
| Genzyme Corporation | $597.65 | 2024-2025 | |
| Boston Scientific Corporation | $443.96 | 2023-2025 | Exalt Model D, General - Endochoice, Speedband Superview Super 7 |
| Janssen Scientific Affairs, LLC | $438.08 | 2022-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $409.01 | 2025 | Iqirvo |
| Lilly USA, LLC | $356.88 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $353.50 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $299.91 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $289.02 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.42 | 2023-2025 | Xifaxan, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $264.28 | 2023 | |
| Intercept Pharmaceuticals, INC. | $258.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.20 | 2022-2025 | Entyvio, Gattex |
| Celltrion USA INC. | $233.20 | 2024-2025 | Vegzelma, Zymfentra |
| Steris Corporation | $216.87 | 2022 | |
| Olympus America INC. | $148.54 | 2022 | |
| Aimmune Therapeutics, INC. | $134.42 | 2023-2025 | Vowst |
| Conmed Corporation | $98.08 | 2025 | Conmed Biliary |
| Daiichi Sankyo INC. | $77.31 | 2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $76.20 | 2023-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $75.13 | 2023-2025 | Rebyota |
| Enterra Medical, INC. | $55.08 | 2024 | |
| Lucid Diagnostics INC. | $43.40 | 2024-2025 | |
| Novo Nordisk INC | $39.12 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $25.29 | 2023 | Suflave |
| Fresenius Kabi USA, LLC | $24.62 | 2024 | Idacio |
| Evoke Pharma, INC. | $17.66 | 2025 | |
| Orphalan INC | $16.50 | 2024 | Cuvrior |
| Sandoz INC. | $16.02 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Muench listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.